Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs

References

• Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24(5):758-64
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 2010;31(5):375-80
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102(4 Pt 1):558-562
   PubMed Web of Science ®Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007(1):CD001936
   PubMed Web of Science ®Google Scholar
• Riechelmann H, Schmutzhard J, Van Der Werf JF, et al. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 2010;24(5):e104-9
   PubMed Web of Science ®Google Scholar
• Wise SK, Schlosser RJ. Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence? Am J Rhinol Allergy 2012;26(1):18-22
   PubMedGoogle Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341(7):468-75
   PubMed Web of Science ®Google Scholar
• Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57(4):306-12
   PubMed Web of Science ®Google Scholar
• Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109(2):251-6
   PubMed Web of Science ®Google Scholar
• Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31(9):1392-7
   PubMed Web of Science ®Google Scholar
• Winther L, Arnved J, Malling HJ, et al. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy 2006;36(3):254-60
   PubMed Web of Science ®Google Scholar
• Cromwell O, Fiebig H, Suck R, et al. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin North Am 2006;26(2):261-81. vii
   PubMedGoogle Scholar
• Senti G, Martinez Gomez JM, Rettig L, et al. Immunotherapeutic targeting of allergic disease. Inflamm Allergy Drug Targets 2006;5(4):243-52
   PubMedGoogle Scholar
• Rolland JM, Gardner LM, O’hehir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 2009;121(3):273-84
   PubMed Web of Science ®Google Scholar
• Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007;119(4):826-30
   PubMed Web of Science ®Google Scholar
• Larche M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007;119(4):906-9
   PubMed Web of Science ®Google Scholar
• Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131(1):103-9. e101-107
   PubMed Web of Science ®Google Scholar
• Pellaton C, Perrin Y, Boudousquie C, et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy 2013;3(1):17
   PubMedGoogle Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105(46):17908-12
   PubMed Web of Science ®Google Scholar
• Senti G, Von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 2011;66(6):798-809
   PubMed Web of Science ®Google Scholar
• Klimek L, Schendzielorz P, Mueller P, et al. Immunotherapy of allergic rhinitis: new therapeutic opportunities with virus-like particles filled with CpG motifs. Am J Rhinol Allergy 2013;27(3):206-12
   PubMedGoogle Scholar
• Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41(9):1305-12
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010;10(11):787-96
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem 2008;389(5):521-36
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22(23-24):3136-43
   PubMed Web of Science ®Google Scholar
• Speiser DE, Schwarz K, Baumgaertner P, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010;33(8):848-58
   PubMed Web of Science ®Google Scholar
• Blaser K. Immunologische Grundlagen der allergenspezifischen Immuntherapie. HNO 2009;8:759-63
   Google Scholar
• Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005;116(5):961-8. quiz 969
   PubMed Web of Science ®Google Scholar
• Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy--T-cell tolerance and more. Allergy 2006;61(7):796-807
   PubMedGoogle Scholar
• Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6(10):761-71
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011;127(1):18-27. quiz 28-19
   PubMed Web of Science ®Google Scholar
• Ruedl C, Bachmann MF, Kopf M. The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur J Immunol 2000;30(7):2056-64
   PubMedGoogle Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. J Control Release 2002;79(1-3):29-40
   PubMed Web of Science ®Google Scholar
• Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001;50(1-2):3-20
   PubMed Web of Science ®Google Scholar
• Reddy ST, Rehor A, Schmoekel HG, et al. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006;112(1):26-34
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008;38(5):1404-13
   PubMed Web of Science ®Google Scholar
• Yewdell JW. Designing CD8+ T cell vaccines: it’s not rocket science (yet). Curr Opin Immunol 2010;22(3):402-10
   PubMedGoogle Scholar
• Tewalt EF, Grant JM, Granger EL, et al. Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. PLoS Pathog 2009;5(5):e1000457
   PubMed Web of Science ®Google Scholar
• Steinman RM, Bonifaz L, Fujii S, et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv Exp Med Biol 2005;560:83-97
   PubMed Web of Science ®Google Scholar
• Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5(12):1219-26
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: past, present and future. Nat Med 2005;11(Suppl 4):S5-11
   PubMed Web of Science ®Google Scholar
• Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005;11(Suppl 4):S63-8
   PubMedGoogle Scholar
• Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011;10(4):499-511
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5(6):471-84
   PubMed Web of Science ®Google Scholar
• Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol 2011;31(1):89-98
   PubMedGoogle Scholar
• Huber JP, Ramos HJ, Gill MA, Farrar JD. Cutting edge: type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 2010;185(2):813-17
   PubMed Web of Science ®Google Scholar
• Fransson M, Benson M, Erjefalt JS, et al. Expression of Toll-like receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis. Respir Res 2007;8:17
   PubMedGoogle Scholar
• Lebre MC, Van Der Aar AM, Van Baarsen L, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2007;127(2):331-41
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kundig TM, et al. The influence of antigen organization on B cell responsiveness. Science 1993;262(5138):1448-51
   PubMed Web of Science ®Google Scholar
• Johnson JE, Chiu W. Structures of virus and virus-like particles. Curr Opin Struct Biol 2000;10(2):229-35
   PubMedGoogle Scholar
• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13(5):552-9
   PubMed Web of Science ®Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117(5):1184-94
   PubMed Web of Science ®Google Scholar
• Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007;4(3):289-94
   PubMedGoogle Scholar
• Dorn A, Kippenberger S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr Opin Mol Ther 2008;10(1):10-20
   PubMedGoogle Scholar
• Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008;3(1):27-32
   PubMedGoogle Scholar
• Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009;61(3):195-204
   PubMed Web of Science ®Google Scholar
• Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003;21(19-20):2461-7
   PubMedGoogle Scholar
• Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004;24(6):693-701
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Kim H, Mccauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005;105(2):489-95
   PubMedGoogle Scholar
• Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115(3):739-46
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008;31(5):520-7
   PubMedGoogle Scholar
• Carpentier A, Laigle-Donadey F, Zohar S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 2006;8(1):60-6
   PubMed Web of Science ®Google Scholar
• Mchutchison JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007;46(5):1341-9
   PubMed Web of Science ®Google Scholar
• Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355(14):1445-55
   PubMed Web of Science ®Google Scholar
• Kundig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117(6):1470-6
   PubMed Web of Science ®Google Scholar
• Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39(4):562-70
   PubMed Web of Science ®Google Scholar
• Hessel EM, Chu M, Lizcano JO, et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med 2005;202(11):1563-73
   PubMed Web of Science ®Google Scholar
• Jagannathan M, Hasturk H, Liang Y, et al. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol 2009;183(11):7461-70
   PubMedGoogle Scholar
• Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004;173(1):531-41
   PubMedGoogle Scholar
• Kline JN. Eat dirt: cpG DNA and immunomodulation of asthma. Proc Am Thorac Soc 2007;4(3):283-8
   PubMedGoogle Scholar
• Mellor AL, Baban B, Chandler PR, et al. Cutting edge: cpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005;175(9):5601-5
   PubMed Web of Science ®Google Scholar
• Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299(6710):1259-60
   PubMed Web of Science ®Google Scholar
• Ball TM, Castro-Rodriguez JA, Griffith KA, et al. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 2000;343(8):538-43
   PubMed Web of Science ®Google Scholar
• Braun-Fahrlander C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002;347(12):869-77
   PubMed Web of Science ®Google Scholar
• Riedler J, Braun-Fahrlander C, Eder W, et al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001;358(9288):1129-33
   PubMed Web of Science ®Google Scholar
• Ito T, Yang M, Wang YH, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007;204(1):105-15
   PubMed Web of Science ®Google Scholar
• Brooks C, Pearce N, Douwes J. The hygiene hypothesis in allergy and asthma: an update. Curr Opin Allergy Clin Immunol 2013;13(1):70-7
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Storni T, Lipowsky G, et al. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 2002;32(11):3305-14
   PubMed Web of Science ®Google Scholar
• Zhang LF, Zhou J, Chen S, et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000;18(11-12):1051-8
   PubMed Web of Science ®Google Scholar
• Hardy CL, Rolland JM, O’hehir RE. Blocking antibodies in allergen immunotherapy: the Yin and Yang. Clin Exp Allergy 2004;34(4):510-12
   PubMedGoogle Scholar
• Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112(5):915-22
   PubMed Web of Science ®Google Scholar
• Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172(5):3252-9
   PubMed Web of Science ®Google Scholar